Mazindol: Difference between revisions
CSV import |
CSV import |
||
| Line 61: | Line 61: | ||
[[Category:Sympathomimetic amines]] | [[Category:Sympathomimetic amines]] | ||
[[Category:Central nervous system stimulants]] | [[Category:Central nervous system stimulants]] | ||
== Mazindol == | |||
<gallery> | |||
File:Mazindol.svg|Mazindol | |||
File:Mazindol3Dan.gif|Mazindol | |||
File:Chemrat Mazindol.svg|Mazindol | |||
File:Mazindol Tautomer Pharmacophore.svg|Mazindol | |||
File:Mazindols 384a-p.svg|Mazindol | |||
File:Mazindols 388a-g.svg|Mazindol | |||
File:Mazindols 389a-c.svg|Mazindol | |||
File:Mazindol analogs 2.svg|Mazindol | |||
File:Mazindol tautomers.svg|Mazindol | |||
File:Mazindol synthesis.svg|Mazindol | |||
File:Mazindol synthesis (alternative).svg|Mazindol | |||
</gallery> | |||
Revision as of 01:28, 20 February 2025
Article about the use of Mazindol in medical treatment
| Mazindol | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Mazindol is a sympathomimetic amine used primarily as an anorectic agent in the treatment of obesity. It functions as a central nervous system stimulant and is chemically related to amphetamine.
Pharmacology
Mazindol acts as a monoamine reuptake inhibitor, primarily affecting the reuptake of norepinephrine and dopamine. This action increases the levels of these neurotransmitters in the synaptic cleft, leading to increased stimulation of the central nervous system.
Medical Uses
Mazindol is prescribed for short-term management of exogenous obesity. It is typically used in conjunction with a reduced-calorie diet and exercise. The drug is intended for patients with a body mass index (BMI) of 30 or greater, or 27 or greater in the presence of other risk factors such as hypertension, diabetes mellitus, or dyslipidemia.
Side Effects
Common side effects of mazindol include:
Serious side effects may include:
Contraindications
Mazindol is contraindicated in patients with:
- Cardiovascular disease
- Hyperthyroidism
- Glaucoma
- History of drug abuse
History
Mazindol was first introduced in the 1970s and was marketed under various brand names, including Sanorex and Mazanor. Its use has declined due to the availability of newer weight-loss medications and concerns about its side effects.
Regulation
Mazindol is classified as a Schedule IV controlled substance in the United States, indicating it has a low potential for abuse relative to substances in Schedule III.
Research
Recent studies have explored the potential use of mazindol in treating narcolepsy and attention deficit hyperactivity disorder (ADHD), due to its stimulant properties.
Also see
References
<references group="" responsive="1"></references>
External links
Mazindol
-
Mazindol
-
Mazindol
-
Mazindol
-
Mazindol
-
Mazindol
-
Mazindol
-
Mazindol
-
Mazindol
-
Mazindol
-
Mazindol
-
Mazindol